Health Catalyst (HCAT)
(Delayed Data from NSDQ)
$7.70 USD
-0.07 (-0.90%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $7.64 -0.06 (-0.78%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.70 USD
-0.07 (-0.90%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $7.64 -0.06 (-0.78%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Zacks News
Health Catalyst (HCAT) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 225% and 3.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 44.12% and 9.85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Does Health Catalyst (HCAT) Have the Potential to Rally 30.43% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 30.4% upside potential for Health Catalyst (HCAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Industry Outlook Highlights Inspire Medical Systems, Olink Holding and Health Catalyst
by Zacks Equity Research
Inspire Medical Systems, Olink Holding and Health Catalyst have been highlighted in this Industry Outlook article.
3 Medical Info Systems Stocks Countering Industry-wide Headwinds
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Inspire Medical Systems (INSP), Olink Holding (OLK) and Health Catalyst (HCAT) are expected to gain even as COVID-19 severity fades.
NextGen (NXGN) Riding on the Success of Cloud-Based Solution
by Zacks Equity Research
NextGen's (NXGN) cloud-based healthcare technology solutions boost the company's prospect. Strong adoption of its services continues to boost revenues.
Health Catalyst (HCAT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 50% and 1.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Olink Holding AB (publ) Sponsored ADR (OLK) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Olink Holding AB (publ) Sponsored ADR (OLK) delivered earnings and revenue surprises of 25% and 0.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Medical Info Systems Stocks Braving Industry-wide Headwinds
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like 10x Genomics (TXG), NextGen Healthcare (NXGN) and Health Catalyst (HCAT) are expected to gain as COVID-19 severity fades.
Does Health Catalyst (HCAT) Have the Potential to Rally 61% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 61.5% upside potential for Health Catalyst (HCAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can Health Catalyst (HCAT) Climb 113% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 113% in Health Catalyst (HCAT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Health Catalyst (HCAT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 35% and 2.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Definitive Healthcare Corp. (DH) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Definitive Healthcare Corp. (DH) delivered earnings and revenue surprises of 20% and 1.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 72.73% and 1.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 25% and 3.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
RadNet (RDNT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of -650% and 1.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
IRhythm Technologies (IRTC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 24.53% and 5.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Inspire Medical Systems (INSP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 21.79% and 6.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 9.52% and 2.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Axonics Modulation Technologies (AXNX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 5.56% and 6.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cerner (CERN) Q4 Earnings Top Estimates
by Zacks Equity Research
Cerner (CERN) delivered earnings and revenue surprises of 5.68% and 2.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -166.67% and 2.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 18.18% and 1.29%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Health Catalyst (HCAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Health Catalyst (HCAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Health Catalyst, DocuSign, American Homes 4 Rent, MidAmerica Apartment Communities and Apartment Income REIT highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Health Catalyst, DocuSign, American Homes 4 Rent, MidAmerica Apartment Communities and Apartment Income REIT highlighted as Zacks Bull and Bear of the Day